First entirely AI developed drug green lit for clinical trial

By Staff Reporter

- Last updated on GMT

(Image: Getty/Metamorworks)
(Image: Getty/Metamorworks)

Related tags: Exscientia, AI, Drug discovery, Sumitomo Dainippon Pharma

A drug candidate for obsessive-compulsive disorder will enter clinical trials, after being discovered and readied in under 12 months.

This rapid turnaround from discovery to clinical trial is part of the reason that industry is excited about the potential for artificial intelligence​. Usually, the drug development pathway averages four and a half years to get to the same stage, noted one of the companies involved, Exscientia.

The drug is DSP-1181, which is a long-acting and potent serotonin 5-HT1A​ receptor agonist, which will enter Phase I trials in Japan for obsessive-compulsive disorder.

The drug candidate was created through the joint research of Japanese pharma company Sumitomo Dainippon Pharma and Exscientia, with the latter providing the Centaur Chemist AI platform for discovery.

Andrew Hopkins, CEO of Exscientia, stated: "We believe that this entry of DSP-1181, created using AI, into clinical studies is a key milestone in drug discovery.”

While the company’s Twitter account​ suggested that it expects all drugs by the end of the decade to be developed using AI.

Several pharma companies have expressed their own confidence in this prospect, with both Sanofi​ and, more recently, Bayer​ entering multi-million drug development deals with the AI specialist.

Related news

Show more

Related products

show more

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us

Products

View more

Webinars